Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care

Cancer remains a major health concern globally. Immune checkpoint inhibitors (ICIs) target co-inhibitory immune checkpoint molecules and have received approval for treating malignancies like melanoma and non-small cell lung cancer. While CTLA-4 and PD-1/PD-L1 are extensively researched, additional t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yao, Li, Zi-Zhan, Zhong, Nian-Nian, Cao, Lei-Ming, Liu, Bing, Bu, Lin-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582482/
https://www.ncbi.nlm.nih.gov/pubmed/37820473
http://dx.doi.org/10.1016/j.tranon.2023.101794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582482/
https://www.ncbi.nlm.nih.gov/pubmed/37820473
http://dx.doi.org/10.1016/j.tranon.2023.101794

Ejemplares similares